Jump to content

Guest

Todd Harrison Discusses Biopharmaceutical Investments

Topic Summary

Created

Last Reply

Replies

Views

Guest -
Money & Finance -
3
152

Top Posters

  • Guest 2
  • Money & Finance 1

Recommended Posts

Guest

Bloomberg Opinion columnist Barry Ritholtz interviews Todd Harrison, a founding partner and chief investment officer at the hedge fund CB1 Capital, which focuses on cannabinoid-based solutions and biopharmaceutical applications and therapies. Prior to his work with CB1 Capital, Harrison spent almost three decades on Wall Street managing risk and researching financial market strategies. He was also the founder and CEO of Minyanville Media Inc., an Emmy-winning financial media company covering global markets in real time.

v3.mp3

    Hello guest!

Share this post


Link to post
Share on other sites

Guest

He mentions the 500 Cannabis related stocks and says 50 are worth investing in of which he wants to hold 25.

Wouldn't we all love to know which 25 those were!

He mentioned this company a few times:

GW Pharmaceuticals is a British biopharmaceutical company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country.[4] Another cannabis-based product, Epidiolex, for treatment of epilepsy, was approved for treatment of epilepsy in 2018.

Share this post


Link to post
Share on other sites

  • Forum Statistics

    59,885
    Total Topics
    107,572
    Total Posts
  • Member Statistics

    16,077
    Total Members
    1,592
    Most Online
    FRANKLIN VARGAS
    Newest Member
    FRANKLIN VARGAS
    Joined




×
×
  • Create New...

Important Information

Terms of Service Confirmation Terms of Use Privacy Policy Guidelines We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.